Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

03. Juni 2020 08:30 ET | Quelle: Ocugen

Ocugen Appoints Dr. Mohamed Genead as Chair of Retina Scientific Advisory Board

MALVERN, Pa., June 03, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare...
01. Juni 2020 09:20 ET | Quelle: Ocugen

Ocugen to Discontinue Phase 3 oGVHD Trial

MALVERN, Pa., June 01, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat the...
08. Mai 2020 07:30 ET | Quelle: Ocugen

Ocugen Provides Business Update and First Quarter 2020 Financial Results

MALVERN, Pa., May 08, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat the...
22. April 2020 09:38 ET | Quelle: Ocugen

Ocugen Announces Completion of Warrant Exchange

MALVERN, Pa., April 22, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare...
07. April 2020 08:01 ET | Quelle: Ocugen

Ocugen Appoints Kirsten Castillo and Prabhavathi Fernandes to Board of Directors

MALVERN, Pa., April 07, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare...
27. März 2020 07:30 ET | Quelle: Ocugen

Ocugen Provides Business Update and Full Year 2019 Financial Results

Over 95% planned enrollment completed in Phase 3 oGVHD study; topline results anticipated by end of 2020 Conference Call and Webcast Today at 8:30 a.m. ET MALVERN, Pa., March 27, 2020 (GLOBE...
20. März 2020 07:30 ET | Quelle: Ocugen

Ocugen to Host Conference Call on Friday, March 27 at 8:30 a.m. ET to Discuss 2019 Financial Results and Provide Business Update

MALVERN, Pa., March 20, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare...
03. März 2020 07:30 ET | Quelle: Ocugen

Nature Gene Therapy Publishes Preclinical Data of Ocugen’s OCU400 (NR2E3-AAV) Genetic Modifier to treat Retinitis Pigmentosa (RP)

MALVERN, Pa., March 03, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare...
10. Februar 2020 07:30 ET | Quelle: Ocugen

Ocugen to Present at NobleCon16 - Noble Capital Markets’ Sixteenth Annual Investor Conference

MALVERN, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare...
09. Dezember 2019 09:29 ET | Quelle: Ocugen

Ocugen Announces Completion of 50% of Enrollment of its Phase 3 Clinical Trial for ocular GVHD

MALVERN, Pa., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ: OCGN), ), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of...

Vorherige Seite